Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 302 posts found.

Breast Cancer Now study to explore personalised drug doses

December 9, 2025
Research and Development Breast Cancer Now, Oncology

Breast Cancer Now has announced a new study to evaluate whether personalised drug doses could improve quality of life for …

News

Samsung Bioepis announces launch of two new denosumab biosimilars in Europe

December 4, 2025
Sales and Marketing Oncology, Osteoporosis, Samsung Bioepis

Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of …

News

Sandoz launches two new bone disease biosimilars in Europe

December 3, 2025
Sales and Marketing Oncology, Osteoporosis, Sandoz

Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the …

News

Medicus Pharma shares updates on basal cell carcinoma trials

December 2, 2025
Research and Development Medicus Pharma, Oncology

Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials studying the efficacy of a …

News

One-carbon Therapeutics starts new cancer therapy trial

November 27, 2025
Research and Development Oncology, One-carbon Therapeutics

Clinical-stage biotechnology company One-carbon Therapeutics has announced that the first subject has been dosed in its clinical trial for TH9619, …

News

Accession Therapeutics doses first patient in new cancer immunotherapy trial

November 26, 2025
Research and Development Accession Therapeutics, Oncology

Biopharmaceutical company Accession Therapeutics has announced the dosing of the first patient in the phase 1 clinical trial of TROCEPT-01 …

News
Press release

ViVac Pharma appoints Keren Leshem as CEO

November 26, 2025
CEO, Oncology, ViVac Pharma

Early-stage biotechnology company ViVac Pharma has appointed Keren Leshem as its new CEO. Leshem brings almost 30 years of experience …

Appointment

Rethinking oncology trial endpoints with generalised pairwise comparisons

November 4, 2025
Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …

Feature

Five Facts about Breast Cancer

October 2, 2025
Medical Communications Breast Cancer Awareness Month, Five Facts, Oncology, breast cancer

1 There are striking inequities in breast cancer burden regarding the Human Development Index (HDI), the United Nation’s measure of …

Feature

Unlocking nature’s pharmacy: how tea leaves and marine organisms could help transform breast cancer treatment

October 2, 2025
Research and Development King Abdullah University of Science and Technology, Oncology, natural products chemistry, triple-negative breast cancer

Looking beyond synthetic chemistry to unlock powerful, naturally derived medicines Each year, World Breast Cancer Awareness Month serves as a …

Feature

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

Feature

Er-Kim to distribute CNX Therapeutics’ oncology drugs across Europe and Turkey

August 29, 2025
Logistics & Distribution, Manufacturing and Production, Mergers and Acquisitions CNX Therapeutics, Corporate, Er-Kim, Oncology, central nervous system disorders, critical care

Turkish pharma company, Er-Kim, has signed a distribution agreement with CNX Therapeutics to expand access to a portfolio of oncology …

News

EMA grants orphan drug designation for Roca’s treatment of radiation maculopathy

August 28, 2025
Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …

News

Neogap Therapeutics appoints Jonas Mattson to its board of directors

August 26, 2025
Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors

Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …

Appointment

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026